- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 131 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- October 2023
- 104 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2023
- 90 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- March 2022
- 86 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- June 2022
- 40 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Book
- July 2023
- 1568 Pages
- Book
- July 2015
- 328 Pages
Praziquantel is a medication used to treat a variety of parasitic infections, including schistosomiasis, tapeworms, and flukes. It is a member of the anthelmintic class of drugs, which are used to treat parasitic worm infections. Praziquantel is the most widely used anthelmintic drug in the world, and is the drug of choice for treating schistosomiasis. It is also used to treat other parasitic infections, such as tapeworms and flukes. Praziquantel is available in both oral and injectable forms, and is generally well tolerated with few side effects.
The market for praziquantel is driven by the prevalence of parasitic infections, particularly in developing countries. The World Health Organization (WHO) estimates that over 1 billion people are infected with parasitic worms, and praziquantel is the drug of choice for treating these infections. The market is also driven by the increasing prevalence of drug-resistant parasites, which require more effective treatments.
The praziquantel market is highly competitive, with several major players. These include Merck & Co., Bayer AG, Sanofi, GlaxoSmithKline, and Pfizer. Other companies in the market include Novartis, Johnson & Johnson, and Teva Pharmaceuticals. Show Less Read more